Christos Kyriakopoulos is an Oncology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
Sponsor: University of Wisconsin, Madison
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GileadProgram year20252 paymentsResearch$61,376openpaymentsdata.cms.gov ↗
- Bristol Myers SquibbProgram year20251 paymentResearch$37,633openpaymentsdata.cms.gov ↗
- ExelixisProgram year20258 paymentsResearch$19,850openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
52.8%Corticosteroid44%Prednisone100%Part D≥34 patientsSerotonin-3 Receptor Antagonist8.8%Ondansetron Hcl100%Part D≥20 patientsCancer & immunology
42.3%Cytochrome P450 17A1 Inhibitor16.6%Abiraterone Acetate100%Part D≥17 patientsKinase inhibitor8.8%Cabometyx52%Lenvima48%Part D<11 patients+ 2 more classes in this area
Anti-infectives
4.9%Short-acting sulfonamides4.9%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2017–2017 per NIH RePORTER. The latest:
- Area C: Functional microscale organotypic assays to predict patient response to anti-angiogenesis therapies
University of Wisconsin-Madison
FY2017$1,491,750R33CA225281
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”